Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the second ...
Every living cell, from the simplest bacterium to a human neuron, relies on the same basic machinery to read, interpret, and use its DNA. This molecular machinery is so fundamental that life as we ...
The pathogenicity of MECP2 C-terminal deletions is determined by translational reading frame, enabling prediction of clinical outcome and a shared therapeutic genome editing strategy.
HNRNPR mutations stop fertilization—PLCζ splicing abnormalities and two therapeutic approaches (AOA and PLCζ supplementation) (Zhejiang University, EMBO Mol Med) Egg activation is essential for ...
ACTRT3 mutations stop fertilization and embryo development—Successful pregnancy achieved with "dual-agent artificial oocyte activation (AOA)" (Sun Yat-sen University) Deficiency of actin-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results